Physician profile
Michael Givens
NPI 1851656771
$628.74
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2021: $12.08 · 2022: $59.73 · 2023: $94.44 · 2024: $40.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $160.35 | 2019-2023 | Proclaim |
| Integra Lifesciences Corporation | $141.51 | 2019 | |
| Medtronic, INC. | $59.73 | 2022 | |
| Nevro Corp. | $47.33 | 2019 | |
| Saluda Medical Americas, INC. | $40.02 | 2024 | Evoke |
| Daiichi Sankyo INC. | $36.36 | 2019 | |
| Zoll Respicardia, INC. | $22.09 | 2023 | Remede System |
| Abiomed | $21.81 | 2023 | Impella |
| Depuy Synthes Sales INC. | $18.79 | 2023 | Monovisc, Orthovisc |
| Amgen INC. | $15.78 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.49 | 2019 | |
| Lilly USA, LLC | $13.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.28 | 2019 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Forte Bio-Pharma LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Givens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.